Clinical Trials Browser

Completed × cediranib × Genitourinary × Clear all

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

Phase 2 Completed

59 enrolled 12 charts

Prostatic Neoplasms

NCT01260688 2018-08-08

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Phase 2 Completed

22 enrolled 23 charts

Prostatic Neoplasms

NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00227760 2016-02-29

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

44 enrolled 8 charts

Carcinoma, Renal Cell

NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male